{"groups":[{"description":"bortezomib, dexamethasone, and thalidomide","id":"FG000","title":"Three Drug Regimen (VDT)"},{"description":"bortezomib, dexamethasone, thalidomide, and cyclophosphamide","id":"FG001","title":"Four Drug Regimen (VDTC)"}],"periods":[{"milestones":[{"achievements":[{"comment":"02 October 2007","groupId":"FG000","numSubjects":"49"},{"comment":"02 October 2007","groupId":"FG001","numSubjects":"49"}],"type":"STARTED"},{"achievements":[{"comment":"10 April 2009","groupId":"FG000","numSubjects":"49"},{"comment":"10 April 2009","groupId":"FG001","numSubjects":"49"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All enrolled patients received at least one dose of study drug.","recruitmentDetails":"98 patients were enrolled between October 2007 and September 2008"}